AMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023
December 14 2022 - 5:08PM
Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and
innovator in seed brachytherapy powering expanding treatment
options throughout the body, today announced that the December
13th, 2022, Annual Meeting is being adjourned until January 12th,
2023, to provide stockholders with additional time to vote on
Proposal 1, approval of an amendment to the Company's Certificate
of Incorporation to increase the total number of authorized shares
of Common Stock. This vote, which requires approval by a majority
of the outstanding shares, is required to proceed with the proposed
merger with Viewpoint Molecular Targeting, Inc.
The Board of Directors, as well as leading proxy advisory firms
Institutional Shareholder Services ("ISS") and Glass, Lewis &
Co., recommend stockholders vote in support of Proposal 1. Proposal
1 approval is necessary for the consummation of the proposed merger
with Viewpoint Molecular Targeting. Proposals 2 and 3 have already
been approved and approval of these two proposals was also required
to consummate the merger.
Stockholders' votes are very important and are critical for
Isoray to move forward with the pending proposed merger with
Viewpoint Molecular Targeting. Management believes that the pending
proposed merger represents a transformational opportunity for
Isoray and all its stockholders. It provides the Company with the
opportunity to combine Isoray's existing business with a pipeline
of very exciting products under development that have the potential
to change the paradigm of patient care in the isotope space.
Proposal 1 requires an affirmative vote of a majority of the
outstanding shares for passage. As of the December 13 meeting date,
Proposal 1 had 52,741,902 shares voting in favor with an additional
18,314,481 shares required for approval. Stockholders who do not
vote are essentially opposing this proposal and as a result, the
proposed merger.
Therefore, the company urges its stockholders who have not yet
cast their vote to please do so. This will help save on further
solicitation costs and ensure that stockholders' important votes
are represented. Stockholders as of the October 20, 2022 record
date can vote, even if they have subsequently sold their
shares.
Voting Instructions - For Shares Held in
"Street" Name
- To vote by
telephone, please call the Company's proxy solicitor, Alliance
Advisors LLC ("Alliance"), at (877) 728-5039. Alliance will assist
with voting questions from 9 a.m. to 10 p.m. Eastern Time, Monday
through Sunday.
- To vote by email,
please contact Alliance at ISR@allianceadvisors.com.
ContactsInvestor Relations: Mark Levin (501)
255-1910Media and Public Relations: Sharon Schultz (302)
539-3747
About IsorayIsoray, Inc. is a medical
technology company pioneering advanced treatment applications and
devices to deliver targeted internal radiation treatments for
cancers throughout the body. Isoray, Inc., through its subsidiary,
Isoray Medical, Inc., is the sole producer of Cesium-131
brachytherapy seeds. Learn more about this innovative Richland,
Washington company and explore the many benefits and uses of
Cesium-131 by visiting www.isoray.com. Follow us on LinkedIn and
Twitter.
Safe Harbor StatementStatements in this news
release about Isoray's future expectations, including: the ability
to get the requisite vote in favor of Proposal 1 and the
anticipated synergies and benefits of the proposed merger with
Viewpoint Molecular Targeting, Inc., and all other statements in
this release, other than historical facts, are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 ("PSLRA"). This statement is included for the
express purpose of availing Isoray, Inc. of the protections of the
safe harbor provisions of the PSLRA. It is important to note that
actual results and ultimate corporate actions could differ
materially from those in such forward-looking statements based on
such factors as whether there is sufficient time to get the votes,
whether the proposed merger with Viewpoint Molecular Targeting,
Inc. is completed and, if so, whether the anticipated benefits of
the merger are realized. Unless required to do so by law, we
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
IsoRay (AMEX:ISR)
Historical Stock Chart
From Aug 2024 to Sep 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Sep 2023 to Sep 2024